GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced BioMedical Technologies Inc (OTCPK:ABMT) » Definitions » EBITDA per Share

Advanced BioMedical Technologies (Advanced BioMedical Technologies) EBITDA per Share : $-0.01 (TTM As of Jul. 2021)


View and export this data going back to 2007. Start your Free Trial

What is Advanced BioMedical Technologies EBITDA per Share?

Advanced BioMedical Technologies's EBITDA per Share for the three months ended in Jul. 2021 was $-0.00. Its EBITDA per Share for the trailing twelve months (TTM) ended in Jul. 2021 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Advanced BioMedical Technologies's EBITDA per Share or its related term are showing as below:

ABMT's 3-Year EBITDA Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.8
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Advanced BioMedical Technologies's EBITDA for the three months ended in Jul. 2021 was $-0.11 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


Advanced BioMedical Technologies EBITDA per Share Historical Data

The historical data trend for Advanced BioMedical Technologies's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced BioMedical Technologies EBITDA per Share Chart

Advanced BioMedical Technologies Annual Data
Trend Oct11 Oct12 Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -

Advanced BioMedical Technologies Quarterly Data
Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Advanced BioMedical Technologies EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Advanced BioMedical Technologies's EBITDA per Share for the fiscal year that ended in Oct. 2020 is calculated as

EBITDA per Share(A: Oct. 2020 )
=EBITDA/Shares Outstanding (Diluted Average)
=-0.283/70.104
=-0.00

Advanced BioMedical Technologies's EBITDA per Share for the quarter that ended in Jul. 2021 is calculated as

EBITDA per Share(Q: Jul. 2021 )
=EBITDA/Shares Outstanding (Diluted Average)
=-0.11/70.465
=-0.00

EBITDA per Share for the trailing twelve months (TTM) ended in Jul. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced BioMedical Technologies  (OTCPK:ABMT) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Advanced BioMedical Technologies EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Advanced BioMedical Technologies's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced BioMedical Technologies (Advanced BioMedical Technologies) Business Description

Traded in Other Exchanges
N/A
Address
200 Park Avenue, Suite 1700, New York, NY, USA, 10166
Advanced BioMedical Technologies Inc is engaged in designing, developing, manufacturing, and the planned future marketing of self-reinforced, re-absorbable biodegradable internal fixation devices. The company manufactures its products using Polyamide, and it is used in a variety of applications, which include orthopaedic trauma, sports-related medical treatment, cartilage injuries, and reconstructive dental procedures. Its Polyamide products include screws, rods, and binding wires consisting of enhanced fibres and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.
Executives
Advanced Biomedical Technologies Inc. director, officer: CFO 200 PARK AVENUE, SUITE 1700 NEW YORK NY 10166
Lynch John Thomas Jr other: Advisor 22 MULBERRY STREET SUITE 1B MIDDLETOWN NY 10940
Chi Ming Yu director, 10 percent owner, officer: PRESIDENT 36 CLAREMONT TERRACE WAYNE NJ 07470
Andriy Protskiv director, 10 percent owner, officer: President, CEO, CFO 706-15038 101 AVENUE SURREY A1 V3R 0N2

Advanced BioMedical Technologies (Advanced BioMedical Technologies) Headlines